Objective To explore the prognosis of patients with BCLC-B hepatocellular carcinoma (HCC) receiving LR + MCT vs TACE.Methods BCLC-B HCC patients undergoing LR + MCT (107 cases) and TACE (65 cases) were retrospectively evaluated,in terms of 30-day mortality rate,the median survival,early and long term survival rate and complications.Results The hospital mortality rate was similar between the two groups (x2 =0.285,P =0.593).However,the LR + MCT group were with a significantly higher postoperative complication rate than the TACE group (x2 =4.694,P =0.03).At the same time,the LR + MCT group had significantly higher median Survival rates (x2 =9.135,P =0.003),but,there was no statistical difference for five-year survival (x2 =4.767,P =0.434).Conclusions LR + MCT are as safe as TACE for patients with BCLC-B HCC,and it provides longer median survival rates.